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Background. Cardiologists are often confronted with patients presenting with chest pain, in
whom clinical risk proﬁling is required. We studied four frequently used risk scores in their
ability to predict for coronary artery disease (CAD) and major adverse cardiovascular events in
patients presenting with stable chest pain at the cardiology outpatient clinic.
Methods and Results. We enrolled 1,296 stable chest pain patients, who underwent cardiac
computed tomographic angiography (CCTA) to assess CAD (any, signiﬁcant: stenosis ‡50%).
Framingham (FRS), PROCAM, SCORE risk score, and Diamond Forrester pre-test proba-
bility were calculated. All patients were followed up for a mean 19 ± 9 months for all
cardiovascular events (mortality, acute coronary syndrome, revascularization >90 days after
CCTA). In ROC-analysis for prediction of signiﬁcant CAD, the areas under the curve for FRS;
0.68 (95% conﬁdence interval: 0.64-0.72) and for SCORE; 0.69 (95% conﬁdence interval: 0.65-
0.72) were signiﬁcantly higher than for PROCAM; 0.64 (95% conﬁdence interval: 0.61-0.68;
P £ .001), as well as marginally higher than for Diamond Forrester; 0.65 (95% conﬁdence
interval: 0.61-0.68; P £ .05). Low FRS category showed the lowest number of patients with
signiﬁcant CAD, compared to patients with low risk using PROCAM, SCORE or Diamond
Forrester (P < .001). Also, low FRS category showed less events (compared to PROCAM and
SCORE; P < .001, for Diamond Forrester; P 5 .14).
Conclusion. Our data show that in a stable chest pain population, the ability of FRS and
SCORE to predict for CAD was similar and better compared to PROCAM and Diamond
Forrester. The number of low risk patients showing signiﬁcant CAD or events was lower using
FRS. Consequently, risk categorization using FRS seems to be safest to stratify stable chest pain
patients prior to CCTA. (J Nucl Cardiol 2011;18:904–11.)
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INTRODUCTION
Cardiovascular disease (CVD) is the leading cause
of death for both men and women in the United States.
1
The CVD epidemic is expected to rise even further and
it is forecasted that by 2030, 40.5% of the US population
will have some form of CVD.
2 Globally, the athero-
sclerotic burden is increasing in an even more rapid
pace, with more expected CVD deaths in India or China
than in all developed countries added together by 2030.
3
In clinical practice, physicians are often confronted
with patients presenting with chest pain, in whom clin-
ical risk proﬁling is required.
4,5 Recently, cardiac
computed tomographic angiography (CCTA) has been
introduced in the clinical workup of chest pain patients.
The excellent negative predictive value of this technique
makes it most suitable to rule out coronary artery disease
(CAD).
6 Although initial reports on diagnostic accuracy
and prognostic value of CCTA are very promising, there
are disadvantages such as the substantial radiation dose
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904and administration of contrast agent. Therefore, most
guidelinesandappropriatenesscriteria recommenduseof
CCTA for the intermediate risk category.
7,8 To assess the
pre-test probability of having CAD prior to CCTA, clin-
ical risk proﬁling is often used. Several algorithms to
assess clinical risk have been developed, which predict
for cardiovascular events in a different way, and are
calibratedindifferentgeographicalregionsandindiverse
patient and population cohorts. Framingham risk score
(FRS) predicts for 10-year risk of having any cardiovas-
cular event, whereas PROCAM predicts for risk of
myocardial infarction only. The SCORE algorithm pre-
dicts for death due to myocardial infarction and not for
disease.Also,noneofthesescoresweredevelopedforuse
in symptomatic patients. The Diamond Forrester pre-test
probability model was developed to assess probability of
having signiﬁcant CAD in symptomatic patients.
9 Yet, it
is not known which algorithm is most suitable to predict
the likelihood of having CAD. The identiﬁcation of the
most precise algorithm to assess the likelihood of CAD is
essential for effective alignment of healthcare resources
and safety of the patient. We studied the most commonly
usedriskproﬁlingalgorithms intheir ability topredictfor
(1) CAD on CCTA, and (2) for major adverse cardio-
vascular events, in patients presenting with chest pain at
the cardiology outpatient clinic.
METHODS
Study Population
Between December 2007 and June 2010, 1,891 patients
presenting with chest pain at our outpatient clinic were
enrolled in this study. Inclusion criteria were a recent history of
cardiac (a)typical chest pain, a diagnostic CCTA scan, deﬁned
as seven or more interpretable coronary segments. Exclusion
criteria were unstable angina, previous myocardial infarction,
previous revascularization, hemodynamic instability, contrast
allergy, pregnancy, and renal failure. In 1,518 patients, a
complete lipid spectrum was collected, Diamond Forrester pre-
test probability, Framingham, PROCAM, and SCORE risk
score were assessed and a CCTA scan was made to assess the
extent of CAD. In 222 subjects, CCTA was excluded because
of artifact formation, or previous revascularization. Eventually,
1,296 subjects were analyzed in this study. Institutional
Review Board and ethics committee at the Maastricht Uni-
versity Medical Center approved the study and all patients
signed informed consent.
Clinical Deﬁnitions
Cardiac risk factors were gathered at the outpatient clinic.
Patients were classiﬁed as active smoker if they had smoked in
the previous 12 weeks. Patients treated with a hypoglycemic
agent or with a fasting plasma glucose C126 mg/dL were
classiﬁed as diabetic. A family history of CAD was deﬁned as
having a ﬁrst-degree relative with a history of myocardial
infarction or sudden cardiac death before the age of sixty.
Diamond Forrester score. The probability of
having signiﬁcant CAD was calculated using the Diamond
Forrester model. This model takes into account age, sex, and
type of chest pain, which was classiﬁed as typical, atypical or
non-anginal.
9 The commonly used classiﬁcation cut-offs of
30% and 70% were used.
10 Consequently, a score below 30%
was considered low, 30%-70% intermediate and [70% high
risk of having signiﬁcant CAD.
Framingham risk score. The Framingham risk
score is a multivariable risk function that predicts 10-year risk
of developing cardiovascular disease events (coronary heart
disease, stroke, peripheral artery disease or heart failure). The
sex-speciﬁc scores incorporate age, total and high-density
lipoprotein cholesterol, systolic blood pressure, treatment for
hypertension, smoking, and diabetic status. A score below 10%
is considered low, 10%-20% intermediate, and [20% high
10-year risk of cardiovascular events.
11
PROCAM risk score. PROCAM participants were
followed up for acute coronary events (myocardial infarction,
sudden cardiac death) for 10 years. The calibrated risk score
included; age, LDL cholesterol, smoking, HDL cholesterol,
systolic blood pressure, family history of premature myocar-
dial infarction, diabetes mellitus, and triglycerides.
12 A score
below 10% is considered low, 10%-20% intermediate, and
[20% high 10-year risk of coronary events.
SCORE risk score. The SCORE predicts 10-year
risk on fatal cardiovascular disease resulted in a model which
included gender, age, systolic blood pressure, total cholesterol,
and smoking. A score of 0%-4% was considered low, 5%-9%




CCTA was performed using a 64-slice CT scanner
(Brilliance 64; Philips Healthcare) with a 64 9 0.625 mm
slice collimation, a gantry rotation time of 420 ms and a tube
voltage of 80-120 kV depending on the patient’s height and
weight. Patients received 5-20 mg of Metoprolol intravenously
to lower the heart rate (HR) \65 bpm as well as sublingual
nitroglycerin spray. HR and ECG were monitored during
CCTA. CCTA was performed using 85-110 mL of contrast
agent (Xenetix 350; Guerbet), which was injected in the
antecubital vein at a rate of 6.0 mL/s, directly followed by
40 mL intravenous saline (6.0 mL/s). In patients with HR
\65 bpm, a prospective-gated ‘‘Step and shoot’’ protocol was
used.
14 In patients with HR [65 bpm, a retrospective-gated
‘‘Helical’’ protocol with dose modulation was used to obtain
the best image quality at minimal radiation dose.
15
CCTA Coronary Plaque Assessment
All CCTA scans were independently analyzed by two
experienced cardiologists, both blinded for patient details. In
case of disagreement, consensus was reached by discussion.
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siﬁcation of the American Heart Association (AHA) in 16
segments was used.
16 The coronary artery tree was assessed
using the source images on the Cardiac Comprehensive
Analysis software (Philips Healthcare). Coronary plaques were
deﬁned as visible structures within or adjacent to the coronary
artery lumen, clearly distinguished from the vessel lumen and
the surrounding pericardial tissue. The degree of stenosis of
atherosclerotic lesions was evaluated visually and classiﬁed as
insigniﬁcant (no lesions, or one or more lesions with luminal
stenosis of \50%), or signiﬁcant (one or more lesions with
luminal stenosis of C50%).
17
Statistics
Data were analyzed using SPSS 17.0 (SPSS Inc). Con-
tinuous variables were reported as means and SDs and
proportions (%) were used for categorical values. Receiver
operating curves (ROC) were produced and area under the
curve (AUC) was reported for different risk scores in relation
to signiﬁcant CCTA lesions. Mc Nemar test was used to assess
signiﬁcance of difference between different risk score cate-
gories. All P values were 2-sided, and a value below 0.05 was
considered signiﬁcant.
Follow-up
Electronic patient records were monitored for all-cause
mortality and acute coronary syndrome (ACS), including
myocardial infarction and unstable angina requiring hospital-
ization. Additionally, the national mortality records were
checked. ACS was deﬁned as typical angina pectoris and tro-
ponin T elevation ([0.01 lg/L) and ST-segment elevation/
depression of C1 mm, or at least two of these symptoms
together with invasive angiographic conformation of a culprit
lesion.
18 Secondary endpoints included percutaneous coronary
intervention (PCI) and coronary artery bypass graft (CABG)
surgery. Revascularization procedures \90 days after CCTA
were excluded as an event, as these would predominantly be
CCTA driven. Further, we censored follow-up after the ﬁrst
endpoint, so that the recorded ACS was not a complication of
revascularization therapy. Patients were seen by their cardiol-




Baseline characteristics are reported in Table 1.O f
1,296 patients, any CAD was found in 62%, signiﬁcant
CAD in 25%. Mean follow-up period was 19 ± 9
months, and a total of 47 events were reported. Events
consisted of 7 deaths, 18 cases of ACS (of which 5 were
diagnosed as myocardial infarction), and 22 cases of
revascularization (15 PCIs and 7 CABGs).
Overall Prediction of CAD per Risk Score
In ROC-analysis for prediction of any coronary
lesion, the areas under the curve for FRS; 0.74 (95%
conﬁdence interval: 0.72-0.77) and for SCORE; 0.72
(95% conﬁdence interval: 0.70-0.75) were signiﬁcantly
higherthanforPROCAM;0.70(95%conﬁdenceinterval:
0.67-0.73; P B .03), which was signiﬁcantly higher than
for Diamond Forrester; 0.65 (95% conﬁdence interval:
0.62-0.68; P\.01), Figure 1. Moreover, the areas under
thecurveforpredictingsigniﬁcantCADstenosisforFRS;
0.68 (95% conﬁdence interval: 0.64-0.72) and for
SCORE; 0.69 (95% conﬁdence interval: 0.65-0.72) were
signiﬁcantly higher than for PROCAM; 0.64 (95% con-
ﬁdence interval: 0.61-0.68; P B .001), as well as
marginally higher than forDiamond Forrester; 0.65(95%
conﬁdence interval: 0.61-0.68; P = .05), Figure 2.
Risk Categorization per Risk Score
Table 2 displays the number (%) of patients per risk
category according to FRS, PROCAM, SCORE, and
Diamond Forrester in relation to CAD and number of
Table 1. Baseline characteristics
Age (years) 56 ± 11
Female gender 606 (46.8)
BMI (kg/m
2)2 7 ± 5
Active smoking 316 (24.4)
Diabetes mellitus 102 (7.9)
Positive family history 522 (40.3)
Systolic blood pressure (mmHg) 142 ± 19
Typical chest pain 169 (13)
Cholesterol (mg/dL)
Total 209 ± 46
LDL 128 ± 42
HDL 51 ± 29
Triglycerides (mg/dL) 153 ± 100
Glucose (mg/dL) 104 ± 24
Creatinin (mg/dL) 1.1 ± 0.2
Clinical risk scores
Framingham 21 ± 16
PROCAM 12 ± 13
SCORE 4 ± 4
Diamond Forrester 42 ± 26
CAD on CCTA
No CAD 490 (37.8)
Insigniﬁcant CAD (\50% stenosis) 489 (37.7)
Signiﬁcant CAD (C50% stenosis) 317 (24.5)
BMI, Body mass index; CAD, coronary artery disease; CCTA,
cardiac computed tomographic angiography; LDL, low-
density lipoprotein; HDL, high-density lipoprotein.
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dictive for CAD (P\.001). Low FRS category showed
the lowest number of patients with signiﬁcant CAD (45/
374 = 12%), compared to patients with low risk using
PROCAM, SCORE or Diamond Forrester (P\.001).
Also, low FRS category showed signiﬁcantly lower
number of events (6/47 = 13%), compared to PRO-
CAM and SCORE (P\.001). When comparing to
Diamond Forrester, however, the number of events was
not signiﬁcantly lower (P = .14). As a consequence,
FRS high risk category included less patients with sig-
niﬁcant CAD and events, compared to patients with high
risk using PROCAM, SCORE or Diamond Forrester
(P B .02). In addition, in the low FRS category, 62%
showed no CAD, compared to 48%, 47%, and 47% for
low PROCAM, SCORE, and Diamond Forrester
(P B .04). Figure 3 provides a visual overview of pro-
portions of CAD in different risk categories, according
to the different scoring models.
DISCUSSION
Our data show that the ability of FRS and SCORE
to predict for CAD was similar and signiﬁcantly better
compared to PROCAM and marginally better than
Diamond Forrester. The number of low risk patients
showing signiﬁcant CAD or events was lower using
FRS, compared to PROCAM, SCORE, and Diamond
Forrester, using the indicated cut-off points for low-,
intermediate- or high-risk for the different algorithms.
Consequently, risk categorization using FRS is safest,
but comes with a cost as more individuals with high risk
do not have signiﬁcant CAD or events, compared to
PROCAM, SCORE, and Diamond Forrester.
The cardiovascular disease epidemic produces a
heavy burden on medical care. As the population ages,
the cardiovascular disease burden will increase and costs
are expected to rise substantially.
2 Consequently, this is
of great concern for physicians confronted with patients
presenting with stable chest pain. The ﬁrst question
clinicians confronted with these patients want answered,
concerns the chance of having CAD, and secondly the
risk of having a cardiovascular event in the future.
Clinical risk proﬁling remains the advised starting point
for evaluation of these patients. Using the most effective
clinical risk proﬁling algorithm is essential, and will
make a substantial difference in risk stratiﬁcation on a
large scale. Above all, effective initial risk stratiﬁcation
will facilitate more efﬁcient use of further diagnostics,
all with their accompanying costs and disadvantages.
With the rapidly expanding epidemic of CAD in
many developing countries, the identiﬁcation of the
most effective algorithm to predict for presence of CAD
is an important step in allocation of appropriate care.
Especially since in most developing countries the
availability of diagnostics is limited and insurance pro-
grams are lacking. The fact that cost-effective use of
health care resources also becomes more and more a
critical issue in Western countries, makes it a global
matter. An additional reason to use the most precise
Figure 1. ROC analysis of Framingham, PROCAM, SCORE,
and Diamond Forrester (DF) score in predicting any lesion on
CCTA, area under the curve is 0.74, 0.72, 0.70, and 0.65,
respectively.
Figure 2. ROC curves for Framingham, PROCAM, SCORE,
and Diamond Forrester (DF) score in predicting C50% lesion
on CCTA, area under the curve is 0.68, 0.69, 0.64, and 0.65,
respectively.
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radiation dose in follow-up diagnostics. Concerns have
been raised about radiation dose and cancer risk implied
by cardiac imaging techniques.
19 Therefore, although
recent innovations in CT scanners have substantially
lowered effective dose, CCTA in stable chest pain
patients is still not generally advised.
20 Most guidelines
ﬁnd CCTA appropriate in stable chest pain patients with
intermediate risk proﬁles.
7,8 In patients with a low risk
proﬁle, the beneﬁts of CCTA do not seem to outweigh
its costs and radiation dose. We showed that when
applying these appropriateness criteria, FRS was safest,
as less patients with any CAD, signiﬁcant CAD or
events were found in the low FRS group, as compared to
the low PROCAM, SCORE group. Also, signiﬁcantly
less patients with any CAD or signiﬁcant CAD were
found in the low FRS group, as compared to the low
Diamond Forrester group.
When using cardiovascular risk proﬁling algorithms
to risk stratify stable chest pain patients prior to CCTA,
one must realize that these scores were developed to
predict coronary heart disease and not coronary athero-
sclerosis. However, there seems to be a strong relation
between coronary atherosclerotic burden and risk of
future coronary heart disease events.
21 We acknowledge
that all scores were based on different risk factors, and
were calibrated on different geographical regions and
populations. Above all, we investigated a symptomatic
population. In contrast to the clinical risk algorithms,
Diamond Forrester pre-test probability score might be
more appropriate for prediction of CAD, but was never
developed to predict for events. Surprisingly, the FRS,
which was calibrated for an American population, per-
formed better than the European calibrated PROCAM
risk score. The major difference between the two algo-
rithms is that FRS includes blood pressure treatment,








































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3. Proportions of signiﬁcant, insigniﬁcant and no CAD
for low-, intermediate-, and high-risk categories by FRS,
PROCAM, SCORE, and Diamond Forrester (DF).
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with previous reports investigating FRS in the PRO-
CAM population. Hense et al reported FRS to
overestimate actual risk in the PROCAM population.
22
For the use of risk stratiﬁcation prior to CCTA, this
overestimation might result in more safety, as we
reported the low FRS category to have less CAD and
events in this study. In SCORE, no glucose or diabetic
status is regarded in the risk score algorithm. Possibly,
this may be a disadvantage in countries were DM is on
the rise. In this study, the performance of Diamond
Forrester seemed to somewhat disappoint. There are
several explanations for this observation. First, the
Diamond Forrester score was developed in 1970s, for
populations undergoing conventional angiography. In
contrast, the current population undergoing CCTA is a
relatively low risk group, in which the majority pre-
sented with atypical chest pain. Eventually, only 25%
showed signiﬁcant coronary stenosis. In addition, there
is evidence that conventional angiography and CCTA
seem to assess the severity of stenosis differently,
especially in non-circular geometry.
23 Furthermore,
although symptoms are incorporated in the Diamond
Forrester score, FRS includes more clinical risk factors.
Given our data, this apparently compensates for the lack
of information about symptoms.
In patients categorized as low risk according to
FRS, still 12% had signiﬁcant lesions in our study. Also,
13% of all events occurred in the low FRS group. This is
in concurrence with previous reports, and questions the
relative safety of using clinical risk proﬁling as a
screening tool in patients with stable chest pain.
24,25
Performance of calcium scoring in addition to clinical
risk proﬁling has shown an increment in predictive value
for CAD and cardiovascular events, and certainly makes
a safer yet more expensive screening tool compared to
clinical risk proﬁling only.
26 There is ample evidence
that calcium score is a good predictor for cardiovascular
events.
26,27 The role of CCTA as a risk predictor is still
more uncertain, although CCTA is reported to have an
excellent negative predictive value,
6 as well as provid-
ing additive value in identifying the patient at risk.
28 In
addition, there is some evidence that CCTA might out-
perform clinical risk proﬁling as well as calcium scoring
in predicting events.
29 Question remains what will be
the most cost-effective strategy on the long term. It is
plausible that more extensive use of imaging techniques
for early detection of patients at risk for CAD can
increment preventive therapy.
30 In the end, prevention
of disease will be more cost-effective compared to
treatment of manifest CAD, and innovations in imaging
techniques such as CCTA will make its application more
justiﬁable, probably even for low risk patients. However,
for now the initial use of clinical risk proﬁling is a
cornerstone in the assessment of patients to be assessed
for CAD and determines the appropriateness of further
CCTA studies. We hereby show that the use of FRS is
safer to engage this role as compared to PROCAM,
SCORE, and Diamond Forrester score.
Study Limitations
The analysis was strengthened by the relatively large
sample size. In general, the study population consisted of
patients of European descent, presenting with both typ-
ical and atypical stable chest pain, in the Netherlands.
Therefore, caution should be taken in interpreting these
study results on other populations, and similar evalua-
tions in different populations and regions worldwide
seem valuable. We used: (1) clinical risk proﬁling
algorithms that were developed to predict different car-
diovascular events within a 10-year period and (2)
Diamond Forrester score which was developed to predict
pre-test probability of signiﬁcant CAD prior to conven-
tional angiography, to predict for CAD as assessed by
CCTA. Although these scores were not developed for
this purpose, there is no designated pre-test probability
score for CCTA yet, resulting in the widespread alter-
native use of these scores. The relative short follow-up
time and small number of events made the data on car-
diovascular events preliminary. We acknowledge the
possibility that events could have presented elsewhere,
resulting in an incomplete follow-up. However, as all
patients were followed up in our clinic, we expect the
completeness of the follow-up to be high.
CONCLUSION
Our data show that in a stable chest pain population
referred for CCTA, the ability of FRS and SCORE to
predict for CAD was similar and signiﬁcantly better
compared to PROCAM and marginally better than
Diamond Forrester. The number of low risk patients
showing signiﬁcant CAD or events was lower using
FRS, compared to PROCAM, SCORE, and Diamond
Forrester, using the indicated cut-off points for low-,
intermediate- or high-risk for the different risk proﬁling
algorithms. Consequently, risk categorization using FRS
seems to be safest in stable chest pain patients, but
comes with a cost as more individuals with high risk will
not have signiﬁcant CAD or events, compared to
PROCAM, SCORE, and Diamond Forrester.
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